Bristol-Myers Squibb Company (BMY) vs State Street SPDR S&P 500 ETF (SPY)
Over the past 10 years, BMY lagged SPY — 2.02% vs 14.89% annualized total return (price plus dividends).
A side-by-side comparison of Bristol-Myers Squibb Company and State Street SPDR S&P 500 ETF across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 28, 2026. Differences are shown without an overall score or investment verdict.
Total return — BMY vs SPY
growth of $100 · dividends reinvested · last 30yMetrics side by side
Did BMY beat SPY?
Over the past 10 years, BMY lagged SPY — 2.02% vs 14.89% annualized total return (price plus dividends).
Total return (annualized)
| Metric | BMY | SPY |
|---|---|---|
| Total return (1Y) | 41.33% | 17.32% |
| Total return CAGR (3Y) | 6.30% | 18.85% |
| Total return CAGR (5Y) | 2.73% | 12.50% |
| Total return CAGR (10Y) | 2.02% | 14.89% |
SPY is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).
Frequently asked
- Has BMY beaten SPY?
- Over the past 10 years, BMY lagged SPY — 2.02% vs 14.89% annualized total return (price plus dividends).
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 28, 2026.